AlphaNavi Pharma Inc.

AlphaNavi Pharma Inc. is a biotechnology startup based in Japan, founded in 2019. The company is focused on developing a unique voltage-gated sodium channel inhibitor, ANP-230, for the treatment of neuropathic pain, particularly targeting Nav1.7, Nav1.8, and Nav1.9. This compound is also aimed at addressing rare pain diseases caused by mutations in these channels. Notably, ANP-230 is one of the few clinical-stage compounds that inhibit Nav1.9. With a successful track record in Phase 1 studies conducted in the US, UK, and Japan, ANP-230 has demonstrated promising tolerability and proof-of-mechanism signals in human pain challenge studies. The company has also received significant backing, with a ¥900.00M Series A investment on 05 April 2019 from a consortium of notable investors including Nippon Venture Capital, SMBC Venture Capital, Shinsei Capital Partners, Dainippon Sumitomo Pharma, Chushin Venture Capital, Kyoto University Innovation Capital, and Chuo Shinkin Venture Capital. Currently, AlphaNavi Pharma is actively pursuing a Phase 1/2 study of ANP-230 for treating Nav1.9 mutated familial episodic limb pain in Japan. In addition, the company is exploring opportunities for out-licensing, aiming to expand the clinical development of ANP-230 in key markets such as the US, EU, and China. With its novel approach and strong investor support, AlphaNavi Pharma is well-positioned in the field of pharmaceutical innovation targeted at addressing unmet medical needs associated with neuropathic pain.